Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
2024年6月26日 - 9:05AM
ビジネスワイヤ(英語)
Conference Call to Take Place Tomorrow,
Wednesday, June 26, 2024, at 8:00am ET
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage
biopharmaceutical company focused on rare respiratory diseases,
today announced that it will host a conference call and webcast
tomorrow, Wednesday, June 26, 2024, at 8:00am ET to discuss top
line results from the pivotal, Phase 3 IMPALA-2 clinical trial
assessing the efficacy and safety of molgramostim, an inhaled form
of recombinant human granulocyte-macrophage colony-stimulating
factor (GM-CSF) in patients with aPAP. The Company plans to issue a
press release sharing the top line results at approximately 6:30am
ET tomorrow, prior to the start of the conference call.
Conference Call
To access the live webcast of the call with slides please click
here or visit the "Events & Presentations" section of Savara’s
website. To access the call by phone, please use this registration
link, and you will be provided with dial-in details. A replay of
the webcast will be available approximately 24 hours after the
conclusion of the call and archived for 90 days under the "Events
& Presentations" section of the Company's website at
www.savarapharma.com.
About Savara
Savara is a clinical stage biopharmaceutical company focused on
rare respiratory diseases. Our lead program, molgramostim nebulizer
solution, is an inhaled granulocyte-macrophage colony-stimulating
factor (GM-CSF) in Phase 3 development for autoimmune pulmonary
alveolar proteinosis (aPAP). Molgramostim is delivered via an
investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our
management team has significant experience in rare respiratory
diseases and pulmonary medicine, identifying unmet needs, and
effectively advancing product candidates to approval and
commercialization. More information can be found at
www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma,
LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240625514690/en/
Savara Inc. IR & PR Anne Erickson
(anne.erickson@savarapharma.com) (512) 851-1366
Savara (NASDAQ:SVRA)
過去 株価チャート
から 8 2024 まで 9 2024
Savara (NASDAQ:SVRA)
過去 株価チャート
から 9 2023 まで 9 2024